In fact, Nrf2 has been implicated to be a mediator of thyroid cancer cell resistance to proteasome inhibitors, suggesting that Nrf2 may play an oncogenic role in thyroid cancer [7, 8]. This evidence concerns the gene NFE2L2 and thyroid cancer.